Thursday, September 14, 2006 Embryonic stages Several Irvine companies are involved in various aspects of the fledgling stem-cell industry. By COURTNEY PERKES The Orange County Register A 21st-century gold rush is under way in California, as researchers at universities and companies mine stem cells that contain the allure of cures.
The tiny cells are the building blocks of the human body, whether in utero or stored in the fat, tissue and blood of adults.
One day, scientists hope, stem cells will yield a wealth of treatments – such as regrowing a missing limb or reversing heart disease – all derived from the elements that make us who we are.
While the federal government has imposed restrictions on embryonic stem-cell research because of ethical concerns, California will spend $3 billion on embryonic stem-cell research to compete in the global industry. Though the bulk of the money is tied up in litigation, Gov. Arnold Schwarzenegger in July agreed to have the state lend the program $150 million until the suit is resolved.
But the research is expensive. And scientists caution that any revolutionary treatments are years away. Still, it's hard to contain the exuberance over a field that could one day yield fortune for sick patients and investors alike.
LifeStem is banking on the discoveries of the future by harvesting adult stem cells that could be unfrozen if treatments someday become available. Novocell is developing embryonic stem-cell lines to seek a cure for diabetes, with a treatment now being tested in animals. And PrimeCell Therapeutics says it has developed a way to transform adult germ stem cells into embryonic-like cells that can morph and multiply. All three companies are in Irvine.
BANKING ON BREAKTHROUGHS Even non-research companies are getting into the business. Clients at Solana MedSpas soon will be offered more than hair plucking and wrinkle removing. LifeStem has teamed up with the health/beauty industry to harvest adult stem cells.
James DeOlden, chief executive of CalbaTech, which owns LifeStem, said the service is not unlike the umbilical-cord blood storage for newborns, which runs about $1,500.
Though he adds for that service, "It's not really a good demographic because most people just bought a house, just got married, just had a kid."
But med spa clients, DeOlden said, fit a different category. They value health and wellness and can afford $3,500 for removal of three vials of blood and fat cells pulled from the abdomen. The stem cells are then removed and frozen at a lab for $200 per year.
"You bank them now because your cells are healthy," DeOlden said. "You don't want to be in a position where you have a disease and there's a therapy available and you don't have healthy cells."
It's the ultimate life insurance policy, says John Buckingham, founder and chief executive of Solana, which has locations in San Clemente, Rancho Santa Margarita and Yorba Linda.
Some stem-cell experts disagree, saying the cells will always be available in the body – if and when disease strikes, and if and when there is a cure.
"It would be the ultimate life insurance if there was actually a guaranteed payoff," said Philip Schwartz, a neural stem-cell researcher at Children's Hospital Orange County. "If I have my fat harvested today and next week I have a spinal cord injury, I don't get anything."
SEEKING TO CURE DIABETES Over the past few years, Novocell has received $33.5 million in grants and venture capital for its work in developing a treatment for diabetes. The company is focused on growing embryonic stem cells to replace islets in the pancreas, which regulate glucose.
Alan Lewis, the company's president and chief executive, said the company has created insulin-producing cells from embryonic stem cells. They are now being tested in rodents to control diabetes.
"It's pretty cool to be able to create these cells from scratch from start to finish," Lewis said. "We've been able to replicate the creation of a human pancreas, if you will, in a dish."
Novocell has already tested a coating that would keep the body from rejecting foreign cells. Islets, which are clusters of cells destroyed by Type I diabetes, have been taken from cadavers and used to treat diabetes in apes and monkeys.
"We think we can cure diabetes," Lewis said. "If it works the way we anticipate, it's going to be a transforming treatment."
The company also has a prominent researcher, Melissa Carpenter, who has worked in the embryonic stem-cell industry since the field was established about a decade ago.
Diabetes groups are keeping a close eye on the company. Over the summer, the company presented an update at the American Diabetes Association meeting in Washington.
"We are supportive of the commercial sector participating in this area and are keeping an eye on companies like Novocell," said Dr. Richard Insel, executive vice president of research for the Juvenile Diabetes Research Foundation. "We are excited by the progress Novocell has made."
If the company can develop a treatment for market, Lewis expects it would be 2013 at the earliest.
"Novocell sounds like the right play," said Christopher Scott, executive director of the Stanford Center for Biomedical Ethics Program on Stem Cells and Society.
"The fact that they're (testing with) primates is a good sign. That shows a financial commitment. Many companies launch right into humans on the basis of mouse data."
A PERSONAL INVESTMENT PrimeCell claims to have reconfigured adult germ cells, which govern reproduction, into cells that can reproduce into any other kind. Such a discovery sidesteps the ethical concerns of embryonic research while overcoming the limitations of adult stem cells, which don't have the capacity to develop into different kinds of cells.
"If you could fully control the human germ line, you come away from any ethical issues. You literally have the holy grail," said Francisco Silva, vice president of research and development. "The other cells you have in your body, they're aged according to your age, except the germ cells.
"The cells, which normally would have been developed into sperm, we've converted into cardiac and brain cells."
Those claims have yet to be substantiated by independent peer review.
"One of the difficulties for the scientific community in terms of judging what PrimeCell has (done) is that they have not published it," said biologist Peter Donovan, co-director of the UCI Stem Cell Research Institute.
Once the work is published, the methodologies can then be examined and judged, Donovan said.
Silva said the study has been accepted for peer review by the journal Nature. The magazine would not comment on submissions.
Schwartz, the CHOC researcher, said he had heard of the company's claim but is waiting to see if the findings are published.
"If you've got something in the stem-cell field that is going to have a big impact, which this would, then Nature should pick it up," he said. "The fact that it's taking so long indicates the reviewers have found some problems with the research that may be something they can solve by doing some additional studies. We have no idea."
The company, started in 2002, is all privately funded and has spent $10 million so far. The primary investor is Thomas Yeun, who along with his 20-year-old daughter suffers from nephritis, a kidney inflammation.
"My intention is to look for an alternative method to deal with current untreatable diseases," Yeun said. "My case is a kidney disease, but it could be any disease that is difficult to heal or cure."
CONTACT US: Register staff writer Yolanda Sanchez contributed to this report. 714-796-3686 or cperkes*ocregister.com
posted
its buy time again for CLBE....remember everytime it hits the .04's buy as much as possible because it will shortly be running back up hopefully this time well over a dime and holding it. Been in constant contact with IR and news is pending (share holder update) which should be released anytime concerning the coast to coast medspa connections.
heres some more related info...
Stem Cell Trials Show Sustained Heart Function Improvement
MELBOURNE, Australia, September 20, 2006 /PRNewswire-FirstCall/ -- Australian adult stem cell company, Mesoblast Limited, today announced positive initial results of clinical adult stem cell trials for the treatment of heart disease being conducted in conjunction with its United States-based sister company Angioblast Systems Inc.
San Francisco, CA (LifeNews.com) Sept. 20, 2006-- At a recent American Chemical Society meeting, teams of stem cell researchers told participants that they can get more out of adult stem cells than previously thought. The scientists said that adult stem cells can become any cell in the body with a little bit of coaxing. Three presentations at the ACS conference touched on the possibility, according to a WebMD report. The papers used different studies by showed similar findings.
The papers all found that adult stem cells taken from bone marrow ordinarily would have become blood cells but can be persuaded to become organ or even nerve cells. The changes occurred when the scientists altered the physical environment in which the cells grew.
Researchers at the University of California, Berkeley used a workout of sorts to prompt adult stem cells to become blood vessel cells. They attached the bone marrow cells to an elastic membrane that stretched and relaxed over the course of several days to get them to grow.
Eventually the adult stem cells turned into smooth muscle cells.
Berkeley scientist Kyle Kurpinski told WebMD, "If a cell cannot flex its muscles like Arnold Schwarzenegger, it cannot build its muscles."
"Gov. Schwarzenegger got big biceps by lifting dumbbells ... It works the same way for stem cells to become smooth muscle cells. They have to sit in culture day in and day out lifting weights," he added.
In a second report, scientists at the University of Pennsylvania told the ACS meeting that new data shows adult stem cells changing into most any environment in which they're inserted.
Penn researchers found that mesenchymal stem cells, which regularly reside in the bone marrow as part of the body's natural regenerative mechanism, can turn into bone, muscle, neurons or other types of tissue depending on the feel of their physical environment.
The adult stem cells depended on physical clues from their local environment in order to transform into different types of tissue.
The third report, given by E. Terry Papoutsakis, Ph.D., professor of chemical and biological engineering at Northwestern University, showed that blood stem cells can become many different kinds of cells. He found that out by manipulating the conditions in which the adult stem cells were grown.
"We demonstrate these cells can do more than is currently accepted," Papoutsakis said, according to the WebMD report. "There are several approaches to harness the potential of the billions of stem cells we make every day."
The studies are good news for patients because adult stem cells have already proven more effective than embryonic ones and have developed dozens of applications for potential cures and treatments
posted
This report, however, may signal a shift in focus by researchers as the plasticity in adult stem cells is better understood. Using autologous stem cells at the time of transplantation might also overcome a major unknown hurdle related to embryonic stem cells, that being possible tissue rejection. Proponents of embryonic stem cell research rarely discuss this potential limitation, while the transplantation of autologous adult stem cells should not result in tissue rejection.
CalbaTech's wholly-owned subsidiary, LifeStem has created a multi-tissue, autologous adult stem cell banking service that allows adults to bank their own stem cells for possible future therapeutic use. LifeStem's Chief Medical Officer, Dr. Jason R. Van Tassel noted that in this study, the cells were generated from adult cultured fibroblasts under specific conditions whereby the cells were grown in the presence of several transcription factors expressed by embryonic stem cells. These cells were then implanted into both mouse embryos and adult mice and differentiated into the three cell lineages seen in early development. This could be the "holy grail" for autologous banking of adult stem cells.
posted
I would seriously like to hear more details on this....
The Company also announced that LifeStem, its wholly owned subsidiary, presented its Stem Cell MicroBank(TM) Service at a national convention of medspa owners and anticipates launching its MicroBank(TM) Service in Florida, New York, North Carolina and other states soon after the August 15th, 2006, California launch date. LifeStem is projecting $3.9 million in revenues in the first twelve months of operating the nation's first service to collect micro-quantities of adult stem cells from multiple tissue sources for future potential therapeutic use.
and thats just the Lifestem division...the others have been far to quiet
posted
lets see how we do after lunch today....although I hate Friday PR's it would be OK if we got a substantial one around 2 or 3 today....then a big EOD rally to follow.....this runs so damn easy on fair volume that any decent buying can blow this past a dime.
Kuldeep Singh, the bus driver who lost his vision in the Delhi blasts last year, has partially regained his vision.
The credit for this goes to Dr Virender Sangwan from Hyderabad's L V Prasad Eye Institute, who has pioneered a unique stem cell technique to restore vision.
When a series of blasts had rocked the capital on October 26, 2005, Kuldeep Singh was alerted about a bomb on the bus he was driving, a few minutes after six that evening.
In minutes, passengers were evacuated. But as he voluntarily threw the bomb out, it exploded. He was seriously injured and lost vision in both his eyes.
Novel therapy
Almost a year on, he has already regained 20 per cent vision and the novel therapy his doctor is using on him, is expected to help him regain half his vision.
Dr Virender Sangwan has worked with patients like Kuldeep, and his technique was to use his own adult stem cells.
These are essentially magical cells that can transform into the living layers needed to restore vision, and he hoped it would restore Kuldeep's sight as well.
Kuldeep first underwent a cornea transplant on his damaged right eye, though his left eye was badly damaged too. Luckily for him, a few live stem cells could still be harnessed from it.
These cells, Dr Sangwan hoped, when grown in the laboratory and introduced in his right eye, would regrow the outer protective layer of the eye enabling him to see.
The procedure helped him regain 20 per cent vision in his right eye. His left eye, however, is dead.
Award winner
Kuldeep was craving to see his newborn son, which was made possible only after this operation.
"I can see if my son is sleeping, or he is moving his hand. I can now see if a car or a bus is moving on the road, and can make out colours as well," said Kuldeep Singh.
Dr Sangwan has used this new stem cell technique on 400 people. Earlier this week Dr Sangwan has been awarded the Bhatnagar award, the Indian version of Nobel prize for developing the new technique.
"We have proof of principle of this in literature, but we have used it in cost effective ways, and also low tech methods. I think we have got the award, because they saw that we have applied it to large population and in difficult cases," said Dr Virender Sangwan.
The technique is not a cure all for kinds of blindness, but only for certain injury-related cases.
Kuldeep needs another minor operation, followed by some additional stem cell therapy to regrow the damaged part. Hopefully then, at least half of his vision might be restored.
And in time, this technology, which comes from the bedside to the bench and then back again to the bedside, can hopefully bring back vision to many more people.
posted
CalbaTech's Subsidiary, LifeStem, Inc., Wins Orange County Innovation Award for Science via COMTEX
October 6, 2006
IRVINE, Calif., Oct 06, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, is pleased to announce that its wholly-owned subsidiary, LifeStem, Inc., has won the 2006 Innovation in Science award presented by Orange County Innovation (OCI).
Along with LifeStem, other 2006 OCI winners include: For Innovation in Technology, The Samueli Foundation; For Innovation in the Arts, The Segerstrom Family; and for Innovation in Technology, EON Reality, Inc.
OCI was formed by top business and community leaders to showcase Orange County, California, as a hotbed of innovation. One of the largest counties in the U.S., with a population of more than three million, it has the 27th largest economy in the world. The award celebrates innovation, which it describes as the ability to create, to invent and to respond to challenges in today's business world with new ideas and strategies.
LifeStem recently introduced the LifeStem MicroBank(TM) Service, its service that allows healthy individuals the ability to collect their own adult stem cells from both peripheral blood and adipose tissue. The stem cells are then cryogenically stored for possible future therapeutic use.
"We are pleased that LifeStem has received this recognition and we're anxious to move forward with LifeStem to show the importance of storing stem cells for future therapeutic use," said James DeOlden, CalbaTech CEO. "We are signing agreements with new collection sites almost every week and are working through logistics related to marketing and training."
Mr. DeOlden recently told Drug Discovery News, a publication serving those interested in the news and business of discovery science, that LifeStem anticipates more than 1,000 clients will take advantage of its service during its first year, with revenues topping $3.9 million. In a September 14th, 2006 article in the Orange County Register, Mr. DeOlden said that stem cells should be banked now, while a person is healthy. "You don't want to be in a position where you have a disease, and there's a therapy available, and you don't have healthy cells." The newspaper said the science of stem cells is creating a "21st-century gold rush" in California.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions. CalbaTech's wholly owned subsidiary LifeStem has developed a unique process to harvest stem cells in micro quantities to be cryopreserved for future transplantation into a client for medical purposes. The collection of stem cells from two different tissue sources increases the potential for treatment of more diseases.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward-looking statements. These forward-looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications, +1-949-707-5365, pknopick*eandecommunications.com, for CalbaTech, Inc. http://www.CalbaTech.com
Copyright (C) 2006 PR Newswire. All rights reserved
Posts: 1580 | From: World | Registered: Jul 2006
| IP: Logged |
wow this may change things for adult cell companines that have been testing for about 50 years >> no cures expected for at least 15 years with embroyonic cells...
posted
Hmmm, 3 white candles. Volume increasing slightly. MACD looks good. Might be ready to pop.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
posted
everyone reckognize this pattern? if not then if your not in CLBE then you may want to grab some soon! Watch for the news coming and also the election campaigns that will push adult stem cell R&D and related issues not to mention the financials due in November and the company WILL be profitable THIS year....yes...2006
posted
Nice buying!!!if your not in CLBE I would advise to take a position now...and I mean now......it appears to be setting up for another run and I feel this time its really going to run hard if we get what we believe we will in the upcoming PR considering projected income and the financials coming in November...the OS is only 96 mill with no dilution for the past 7 months and a self supporting company with multiple profitable divisions.....lets hope we have a dollar stock here soon.
posted
I hope you're right Quest. Next uptick and I'll be back to even on this. But I'm looking for a lot more then even.
Posts: 134 | From: PA | Registered: Mar 2006
| IP: Logged |
posted
for those who may have missed this.....and this will put CLBE into 50 more addition locations not to mention the project 38 to 50 more this year thru Solena!!
MedSpas Partners With Solana MedSpas to Launch Chain of Boutique Medical Spas Market Wire - October 17, 2006 12:13 PM ET
MedSpas of America, Inc. (PINKSHEETS: MDSP), www.medspasofamerica.com, today announces that it has signed a Joint Venture Development Agreement with Solana MedSpas of Irvine, California.
Under the terms of the MedSpa Development Joint Venture, Solana MedSpas has agreed to provide development services and operational oversight to MDSP with the intent to build a company owned chain of a minimum of 50 Medical Spas, under the brand name of Virtuoso Medical Spas, in the United States over the next 5 years. The services provided by Solana will include site selection and build-out of new MedSpas, design services, equipment and supplies procurement, medical protocol and operating systems, recruitment and training of MedSpa staffing, medical regulatory compliance, and marketing programs. Both Solana MedSpas and MSAP have agreed to focus the company's initial development program on the acquisition and conversion of existing MedSpa businesses that are not currently in the national Solana MedSpas network.
Paul R. Smith, CEO of MDSP, said: "The experience that Solana's management team has in developing MedSpas is unprecedented in the industry. Our joint venture with Solana MedSpas brings incredible depth into our management team. The systems and expertise Solana MedSpas provides will accelerate our growth and minimize our mistakes along the way. I am very proud that a company with the reputation of Solana MedSpas has joined forces with us."
"We are delighted to be partnering with MDSP! Their business plan and strong financial resources enable Solana MedSpas to accelerate its business plan to add new MedSpa locations across the U.S. at a faster rate," said John Buckingham, Chairman, CEO and Co-Founder of Solana MedSpas.
About Solana MedSpas
Founded in July 2003, Solana MedSpas has created a new market segment by combining aesthetic healthcare in conjunction with the spa movement, coming from the medical, regulatory and educational approach. Moving beyond aesthetic medical treatments, Solana MedSpas is the nation's first MedSpa network to offer a broader range of medical treatments in a retail spa environment. Solana MedSpas provides the industry's only model for a legally compliant, competitive, and forward-thinking business in all 50 states.
Solana MedSpas has 30 Medical Spas open to date and another 20 slated to open by end of year 2006 in 21 states representing 50 trade areas. Solana MedSpas plans to grow the network to a total of 100 locations by 2007. For more information on Solana MedSpas call 949-223-6444 or visit www.solanamedspas.com
About MedSpas of America, Inc.
MedSpas of America, Inc., www.medspasofamerica.com, is dedicated to the development and operations of MedSpas throughout the United States under the brand name of Virtuoso Medical Spas. Virtuoso was founded by leading practitioners and accomplished executives in response to the growing marketplace demand for technology-based medical spa facilities that are committed to professional skin care.
posted
Quest, I'll take these 5-10% increases everyday. Soon we'll be at 10 cents, and will have flown under the radar the whole time.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
posted
Looking even better on the bid side now!! like to see this close in the .06's or more but still quite happy with the small gains each day and .05's will be fine!
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
Originally Posted by extremeok this has got to be the next rage among Hollywood stars, the series nip/tuck had a few episodes with a medspa in it. a lot of people watch and i didn't know they existed until i watched the series. sheltered life.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
posted
at the break out pivot point now between .052 and .055.....volume slowed but thats typical for Friday until near close....hope we don't get another Friday PR and they hold of a killer info package until Monday or Tuesday!
Business Description: Calbatech offers products and platforms to the life sciences research market. Through its three divisions (Molecular Applications, Research Reagents, and Cellular Therapeutics) and several wholly owned subsidiaries (Molecula, KD Medical, LifeStem, and MolecularWare), the company is actively developing breakthrough innovations in biological discovery
posted
I do think this is going to move differantly this time and even though we definitely will have some exits on the way up of those that have patiently been in this for months I think the shares will be absorded relatively quickly but the PPS support should still be strong.The financials now will look much better this quarter due to they can now add 2 other divisions that was down under consolidation for 2 months out of 3 and they still did fair....this time they will get the full quarter I also don't think it will take 8 to 10 mill in volume either,I personally like seeing the increase on low volume and we all already know the shares have been held tight and right of the top 25% or more is locked up by insiders......I think once this settles down above a dime and consolidates there for a bit it will start to get even more attention.They are definitely getting thier name out...the e-mail I sent to the Governor of Maryland apparently got their attention since the response they sent me (via snail mail) clearly shows they are already familiar with the company name and they also mentioned KD Medical thats located here.I think once this starts to really move many will realize that they are the REAL deal and well worth an investment.......whats so good about CLBE's Lifestem division is that it compliments all other stem cell companies that we may eventually find out that other stem cell companies are going to directly hire us for the micro-banking for their clients just like we already lease clean room space and labs in our other divisions
The market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 (Source DMD). This is projected due to the growth of new cellular therapeutics based on embryonic and adult stem cells, as well as clinical applications to compete with, or complement, existing drug based therapeutics. LifeStem's strategy is to leverage the CalbaTech infrastructure of companies to obtain a leadership position in the fast emerging stem cell collection arena and become the preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services. In time, it is anticipated that elements of LifeStem's services will become standard practice in mainstream clinical applications, thus opening a much larger market to LifeStem as a cellular logistics services company.
LifeStem is positioning itself to become a leading supplier of "Cellular Logistics" in this large new market. The company is focused on the following: (1) Providing a Stem Cell Microbank(TM) service to individuals; (2) Providing services and technologies to facilitate the efficient acquisition and delivery of purified adult stem cells to the research market and; (3) Developing delivery devices for clinical applications.
if financials keep this up...clbe will be worth a lot more than .05...especially with LifeStem kicking into high gear.
and i cannot see anything holding financials back..maybe some residual effect from the move, but that is only temporary and will ultimately lead to stronger revenue moving forward.
The Company announced a net loss for the year of $5 million, incurring an unrealized one-time loss in recording the fair value of the debenture and related warrant derivatives relating to the convertible notes it obtained in 2005. The total non-cash financial impact to CalbaTech's income statement amounted to $2.3 million and the Company also incurred non-cash interest costs of $916,232 relating to the convertible debt accretion. CalbaTech said it anticipates realizing a gain of $4.15 million pursuant to this one-time loss in the year ending 2006. CalbaTech said it expects significant progress in 2006 by its wholly own subsidiary, LifeStem, and its Stem Cell Microbank(TM) Service, which collects and stores healthy adult stem cells for autologous use.
posted
Don't forget...we have patents pending that could be announced approved anytime now!
[SIZE="4"]CalbaTech LifeStem Subsidiary Files for Key Patent for Its Stem Cell Delivery Device[/SIZE]Tuesday June 14, 5:00 am ET
IRVINE, Calif., June 14 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., has filed a U.S. Patent Application for its Stem Cell Delivery Device. The patent is for the Device and Methods for Treatment of Necrotic Tissue using Stem Cells.
The Stem Cell Delivery Device, for which the utility patent was filed, is a system for the regeneration of cardiac muscle post myocardial infarction. This apparatus is designed for the targeted delivery of peripheral blood-derived autologous adult stem cells to diseased tissue for the purpose of regenerating healthy functional tissue. The Company believes that adult stem cells have tremendous potential to promote the regeneration of dead or diseased cardiac tissue.
"We are pleased that research continues to show that adult stem cells provide significant promise for restorative therapies," said LifeStem President Dan Fulkerson. "LifeStem is committed to its plan to continue to work with adult stem cells and to further develop our delivery of stem cells into diseased heart tissue through our proprietary system," said Mr. Fulkerson. "The Company continues to move forward expeditiously in the stem cell arena, which holds the promise of conquering some of mankind's most dreaded diseases."
Current scientific data supports the contention that stem cells hold huge promise for the treatment, cure and possible prevention of numerous diseases including heart disease and Parkinson's Disease, as well as spinal cord injuries. Recent data has indicated that if adult autologous (one's own) stem cells are reintroduced to the donor, it could provide advantages similar to embryonic stem cells without the risk of rejection.
About LifeStem Inc.
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics". The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of purified adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
